Chemomab Therapeutics (CMMB) announced that David Weiner, MD, has been named Interim Chief Medical Officer, CMO, and Jack Lawler, Senior Vice President of Global Medical Operations at Chemomab, has been named Chief Development Officer, CDO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMMB:
- Promising Phase 3 Prospects and Strategic Study Design Justify Buy Rating for Chemomab Therapeutics
- Chemomab’s Nebokitug Shows Promising Phase 2 Results for PSC
- Chemomab Therapeutics reports results in nebokitug Phase 2 PSC OLE trial
- Chemomab Therapeutics Updates ADS Offering Under Sales Agreement
- Chemomab Therapeutics Reports 2024 Financial Results and Progress